Email the editor

UBM cementing position in Asia with pharma brands

Nearly 8,000 visitors and more than 450 exhibitors attend CPhI Russia and CPhI South East Asia

Pictured: Chris Kilbee

UBM EMEA has cemented its position in Asia with two successful events, CPhI Russia and CPhI South East Asia - the largest pharma events in their respective regions.

CPhI South East Asia 2016 saw 4,740 attendees from 41 countries and witnessed a participation of 260 exhibitors from 25 countries. Meanwhile, CPhI Russia welcomed 199 exhibitors and attracted more than 3,000 attendees from 63 countries across the globe.

Chris Kilbee, group director pharma at UBM EMEA, said: “With now four market-leading events in Asia, CPhI Russia and CPhI South East Asia demonstrate the continued growth and recognition of the CPhI portfolio around the globe. Much of this is due to our ability to provide practical and innovative solutions tailored to regional markets – both from an exhibitor and, just as crucially, from a visitor perspective.”

In the past few years, CPhI has been introducing its worldwide brand into new and emerging pharma markets, as well as incorporating customer feedback and local conditions. 

In 2016, CPhI Russia and South East Asia both featured a matchmaking programme, designed to ensure the event delivered relevant meetings to its attendees. 

Widening the scope of its platform, CPhI Russia also ran parallel conferences to the event - the IPhEB forum. Alongside this, the exhibition offered paid-for opportunities for exhibitors and a new exhibitor awards platform. 

A notable feature at CPhI South East Asia was the Innovation Gallery, which showcased the most innovative exhibitor products.

Mirroring local market conditions, this year CPhI South East Asia took the decision to incorporate the first editions of sister brands ICSE and Health Ingredients (Hi). In just its first year, the two-day conference platform gathered 276 delegates.

Kilbee commented: “At CPhI we have made a concerted effort to be as close to our attendees as possible. Our events have been able to seamlessly switch between markets as they combine a core international audience, alongside essential local market knowledge and analysis. Our ambition in these emerging and fast growing pharma economies is to remain flexible and adaptive, but to grow the event numbers in line with the huge potential in these two healthcare economies.”

Facebook Share Twitter Share LinkeIn Share